Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Transl Lung Cancer Res. 2014 Dec;3(6):395-6. doi: 10.3978/j.issn.2218-6751.2014.09.03.

¹ Chris O'Brien Lifehouse, Department of Medical Oncology, Camperdown, NSW 2050, Australia.

No abstract available